Clinical Center; Notice of Closed Meeting, 49285 [07-4196]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 166 / Tuesday, August 28, 2007 / Notices
pwalker on PROD1PC71 with NOTICES
are risk factors for infertility, the
transmission of HIV, and human
papilloma virus-induced cervical
neoplasia. Control of C. trachomatis
infections is an important public health
goal. Unexpectedly, however, aggressive
infection control measures based on
early detection and antibiotic treatment
have resulted in an increase in infection
rates, most likely by interfering with
natural immunity, a concept suggested
by studies performed in experimental
infection models. Effective management
of chlamydial disease will likely require
the development of an efficacious
vaccine.
This technology claims vaccine
compositions that comprise an
immunologically effective amount of
PmpD protein from C. trachomatis. Also
claimed in the application are methods
of immunizing individuals against C.
trachomatis. PmpD is an antigenically
stable pan-neutralizing target that, in
theory, would provide protection
against all human strains, thus allowing
the development of a univalent vaccine
that is efficacious against both blinding
trachoma and sexually transmitted
disease.
Application: Prophylactics against C.
trachomatis.
Developmental Status: Preclinical
studies have been performed.
Inventors: Harlan Caldwell and
Deborah Crane (NIAID).
Publication: DD Crane et al.
Chlamydia trachomatis polymorphic
membrane protein D is a speciescommon pan-neutralizing antigen. Proc.
Natl Acad Sci USA. 2006 Feb
7;103(6):1894–1899. Epub 2006 Jan 30.
Patent Status: PCT Patent Application
No. PCT/US2007/001213 filed 16 Jan
2007 (HHS Reference No. E–031–2006/
0–PCT–02).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Peter A. Soukas,
J.D.; 301/435–4646;
soukasp@mail.nih.gov.
Collaborative Research Opportunity:
The NIAID, Laboratory of Intracellular
Parasites, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize PmpD vaccine
development. Please contact Harlan D.
Caldwell, at hcaldwell@niaid.nih.gov or
406/363–9333 for more information.
Dated: August 21, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–16935 Filed 8–27–07; 8:45 am]
BILLING CODE 4140–01–P
VerDate Aug<31>2005
19:52 Aug 27, 2007
Jkt 211001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Clinical Center; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
Board of Scientific Counselors of the
NIH Clinical Center.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
Clinical Center, including consideration
of personnel qualifications and
performance, and the competence of
individual investigators, the disclosure
of which constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Board of Scientific
Counselors of the NIH Clinical Center.
Date: September 24–25, 2007.
Time: 8 a.m. to 12 p.m.
Agenda: To review and evaluate the
Critical Care Medicine Program.
Place: National Institutes of Health,
Building 10, 10 Center Drive, CRC Room 4–
2551, Bethesda, MD 20892.
Contact Person: David K. Henderson, MD,
Deputy Director for Clinical Care, Office of
the Director, Clinical Center, National
Institutes of Health, Building 10, Room 6–
1480, Bethesda, MD 20892, (301) 496–3515.
Dated: August 20, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–4196 Filed 8–27–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the meeting of the
National Cancer Advisory Board.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
49285
notify the Contact Person listed below
in advance of the meeting.
A portion of the meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(4) and 552b(c)(6), as amended.
The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Advisory Board.
Open: September 17, 2007, 8:30 a.m. to
4:15 p.m.
Agenda: Program reports and
presentations; Business of the Board.
Place: National Cancer Institute, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Contact Person: Dr. Paulette S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Room 8001,
Bethesda, MD 20892–8327, (301) 496–5147.
Name of Committee: National Cancer
Advisory Board.
Closed: September 17, 2007, 4:15 p.m. to
5:30 p.m.
Agenda: Review of grant applications.
Contact Person: Dr. Paulette S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Room 8001,
Bethesda, MD 20892–8327, (301) 496–5147.
Name of Committee: National Cancer
Advisory Board.
Open: September 18, 2007, 8 a.m. to 12
p.m.
Agenda: Program reports and
presentations; Business of the Board.
Contact Person: Dr. Paulette S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Room 8001,
Bethesda, MD 20892–8327, (301) 496–5147.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page:
deainfo.nci.nih.gov/advisory/ncab.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
E:\FR\FM\28AUN1.SGM
28AUN1
]]>Agencies
[Federal Register Volume 72, Number 166 (Tuesday, August 28, 2007)]
[Notices]
[Page 49285]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-4196]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Clinical Center; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of
the Board of Scientific Counselors of the NIH Clinical Center.
The meeting will be closed to the public as indicated below in
accordance with the provisions set forth in section 552b(c)(6), Title 5
U.S.C., as amended for the review, discussion, and evaluation of
individual intramural programs and projects conducted by the Clinical
Center, including consideration of personnel qualifications and
performance, and the competence of individual investigators, the
disclosure of which constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Board of Scientific Counselors of the NIH
Clinical Center.
Date: September 24-25, 2007.
Time: 8 a.m. to 12 p.m.
Agenda: To review and evaluate the Critical Care Medicine
Program.
Place: National Institutes of Health, Building 10, 10 Center
Drive, CRC Room 4-2551, Bethesda, MD 20892.
Contact Person: David K. Henderson, MD, Deputy Director for
Clinical Care, Office of the Director, Clinical Center, National
Institutes of Health, Building 10, Room 6-1480, Bethesda, MD 20892,
(301) 496-3515.
Dated: August 20, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-4196 Filed 8-27-07; 8:45 am]
BILLING CODE 4140-01-M
